GHRS - GH Research PLC
IEX Last Trade
10.39
-0.580 -5.582%
Share volume: 21,859
Last Updated: Fri 30 Aug 2024 09:59:58 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$10.97
-0.58
-5.29%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-8.54%
1 Month
-13.79%
3 Months
-22.39%
6 Months
27.58%
1 Year
-1.87%
2 Year
-30.83%
Key data
Stock price
$10.39
DAY RANGE
$10.17 - $11.07
52 WEEK RANGE
$5.05 - $14.99
52 WEEK CHANGE
$0.01
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Theis Terwey
Region: US
Website:
Employees: 9
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website:
Employees: 9
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
gh research is a privately-held clinical-stage biopharmaceutical company developing novel therapies for the management of mental illness.
Recent news